FOXL2 and blepharophimosis, ptosis, and epicanthus inversus syndrome: Heterozygous intragenic variants of FOXL2 accounted for 71% of patients with blepharophimosis-ptosis-epicanthus inversus syndrome (BPES), which is a dominant condition characterized by eyelid and mild craniofacial defects associated with POI (type I) or not (type II) [17].